Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis

By Soverini Simona   Martinelli Giovanni   Rosti Gianantonio   Iacobucci Ilaria   Baccarani Michele  

Pharmacogenomics, Vol. 13, Iss. 11, 2012-08 ,pp. : 1271-1284

Future Medicine

Access to resources Recommend Favorite

Treatment of Chronic Myeloid Leukemia Elderly Patients in the Tyrosine Kinase Inhibitor Era

By  

Current Cancer Drug Targets, Vol. 13, Iss. 7, 2013-09 ,pp. : 755-767

Bentham Science Publishers

Access to resources Recommend Favorite

Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients

By  

Current Cancer Drug Targets, Vol. 12, Iss. 4, 2012-04 ,pp. : 391-401

Bentham Science Publishers

Access to resources Recommend Favorite

Monitoring Chronic Myelogenous Leukemia in the Age of Tyrosine Kinase Inhibitors

By Radich Jerald P.   Oehler Vivian  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 5, Iss. 5, 2007-05 ,pp. : 497-504

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

New Opportunities to Treat the T315I-Bcr-Abl Mutant in Chronic Myeloid Leukaemia: Tyrosine Kinase Inhibitors and Molecules that Act by Alternative Mechanisms

By  

Current Medicinal Chemistry, Vol. 17, Iss. 13, 2010-05 ,pp. : 1220-1245

Bentham Science Publishers

Access to resources Recommend Favorite